Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Sigurjonsson, Olafur Eysteinn
MetadataShow full item record
CitationConstantinescu C, Pasca S, Tat T, et al. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. J Immunother Cancer. 2020;8(1):e000742. doi:10.1136/jitc-2020-000742
AbstractRecently, an increasing number of novel drugs were approved in oncology and hematology. Nevertheless, pharmacology progress comes with a variety of side effects, of which cytokine release syndrome (CRS) is a potential complication of some immunotherapies that can lead to multiorgan failure if not diagnosed and treated accordingly. CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. This, in turn, leads to a proinflammatory state with subsequent organ damage. To better manage CRS there is a need for specific therapies or to repurpose strategies that are already known to be useful in similar situations. Current management strategies for CRS are represented by anticytokine directed therapies and corticosteroids. Based on its pathophysiology and the resemblance of CRS to sepsis and septic shock, as well as based on the principles of initiation of continuous renal replacement therapy (CRRT) in sepsis, we propose the rationale of using CRRT therapy as an adjunct treatment in CRS where all the other approaches have failed in controlling the clinically significant manifestations.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
Rights© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
- The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China.
- Authors: Xiang H, Song B, Zhang Y, Zhang J, Xiong J
- Issue date: 2021 Apr 3
- Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series.
- Authors: Alharthy A, Faqihi F, Memish ZA, Balhamar A, Nasim N, Shahzad A, Tamim H, Alqahtani SA, Brindley PG, Karakitsos D
- Issue date: 2021 May
- Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
- Authors: Cosenza M, Sacchi S, Pozzi S
- Issue date: 2021 Jul 17
- Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.
- Authors: Khadka RH, Sakemura R, Kenderian SS, Johnson AJ
- Issue date: 2019 Jul
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
- Authors: Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS
- Issue date: 2019 Apr